Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review Article
  • Published:

p53-regulated lncRNAs in cancers: from proliferation and metastasis to therapy

Cancer Gene Therapy volume 30, pages 1456–1470 (2023)Cite this article

Subjects

Abstract

Long non-coding RNAs (lncRNAs) have been identified as master gene regulators through various mechanisms such as transcription, translation, protein modification and RNA-protein complexes. LncRNA dysregulation is frequently associated with a variety of biological functions and human diseases including cancer. The p53 network is a key tumor-suppressive mechanism that transcriptionally activates target genes to suppress cellular proliferation in human malignancies. Recent research indicates that lncRNAs play an important role in the p53 signaling pathway. In this review, we summarize the current knowledge of lncRNAs in p53-relevant functions and provide an overview of how these altered lncRNAs contribute to tumor initiation and progression. We also discuss the association between lncRNA and up- or downstream genes of p53. These findings imply that lncRNAs can help identify cellular vulnerabilities that may prove to be promising potential biomarkers and therapeutic targets for cancer treatment.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: The Molecular Mechanisms of lncRNAs.
Fig. 2: lncRNA encodes small peptides.
Fig. 3: The hallmarks and enabling characteristics of p53 in cancer.
Fig. 4: The p53-related lncRNA in cancer.

Similar content being viewed by others

Data availability

Data sharing is not applicable in this article as no new data was created or analyzed in this study.

References

  1. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature. 1991;351:453–6.

    Article  CAS  PubMed  Google Scholar 

  2. Lane DP, Benchimol S. p53: oncogene or anti-oncogene? Genes Dev. 1990;4:1–8.

    Article  CAS  PubMed  Google Scholar 

  3. Freed-Pastor WA, Prives C. Mutant p53: one name, many proteins. Genes Dev. 2012;26:1268–86.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Braithwaite AW, Sturzbecher HW, Addison C, Palmer C, Rudge K, Jenkins JR. Mouse p53 inhibits SV40 origin-dependent DNA replication. Nature. 1987;329:458–60.

    Article  CAS  PubMed  Google Scholar 

  5. Marur S, D’Souza G, Westra WH, Forastiere AA. HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol. 2010;11:781–9.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Lane DP. Cancer. p53, guardian of the genome. Nature. 1992;358:15–6.

    Article  CAS  PubMed  Google Scholar 

  7. Bykov VJN, Eriksson SE, Bianchi J, Wiman KG. Targeting mutant p53 for efficient cancer therapy. Nat Rev Cancer. 2018;18:89–102.

    Article  CAS  PubMed  Google Scholar 

  8. Engeland K. Cell cycle regulation: p53-p21-RB signaling. Cell Death Differ. 2022;29:946–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Liu T, Lam V, Thieme E, Sun D, Wang X, Xu F, et al. Pharmacologic targeting of Mcl-1 induces mitochondrial dysfunction and apoptosis in B-cell lymphoma cells in a TP53- and BAX-dependent manner. Clin Cancer Res. 2021;27:4910–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Wang J, Thomas HR, Li Z, Yeo NCF, Scott HE, Dang N, et al. Puma, noxa, p53, and p63 differentially mediate stress pathway induced apoptosis. Cell Death Dis. 2021;12:659.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Aubrey BJ, Kelly GL, Janic A, Herold MJ, Strasser A. How does p53 induce apoptosis and how does this relate to p53-mediated tumour suppression? Cell Death Differ. 2018;25:104–13.

    Article  CAS  PubMed  Google Scholar 

  12. Kim E, Giese A, Deppert W. Wild-type p53 in cancer cells: when a guardian turns into a blackguard. Biochem Pharm. 2009;77:11–20.

    Article  CAS  PubMed  Google Scholar 

  13. Zhu J, Sammons MA, Donahue G, Dou Z, Vedadi M, Getlik M, et al. Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth. Nature. 2015;525:206–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Duffy MJ, Crown J. Drugging “undruggable” genes for cancer treatment: Are we making progress? Int J Cancer. 2021;148:8–17.

    Article  CAS  PubMed  Google Scholar 

  15. Birsen R, Larrue C, Decroocq J, Johnson N, Guiraud N, Gotanegre M, et al. APR-246 induces early cell death by ferroptosis in acute myeloid leukemia. Haematologica. 2022;107:403–16.

    Article  CAS  PubMed  Google Scholar 

  16. Hong Y, Ren T, Wang X, Liu X, Fei Y, Meng S, et al. APR-246 triggers ferritinophagy and ferroptosis of diffuse large B-cell lymphoma cells with distinct TP53 mutations. Leukemia. 2022;36:2269–80.

    Article  CAS  PubMed  Google Scholar 

  17. Consortium EP, Birney E, Stamatoyannopoulos JA, Dutta A, Guigo R, Gingeras TR, et al. Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature. 2007;447:799–816.

    Article  Google Scholar 

  18. Toden S, Zumwalt TJ, Goel A. Non-coding RNAs and potential therapeutic targeting in cancer. Biochim Biophys Acta Rev Cancer. 2021;1875:188491.

    Article  CAS  PubMed  Google Scholar 

  19. Palazzo AF, Koonin EV. Functional long non-coding RNAs evolve from junk transcripts. Cell. 2020;183:1151–61.

    Article  CAS  PubMed  Google Scholar 

  20. Esteller M. Non-coding RNAs in human disease. Nat Rev Genet. 2011;12:861–74.

    Article  CAS  PubMed  Google Scholar 

  21. Ali SA, Peffers MJ, Ormseth MJ, Jurisica I, Kapoor M. The non-coding RNA interactome in joint health and disease. Nat Rev Rheumatol. 2021;17:692–705.

    Article  CAS  PubMed  Google Scholar 

  22. Goodall GJ, Wickramasinghe VO. RNA in cancer. Nat Rev Cancer. 2021;21:22–36.

    Article  CAS  PubMed  Google Scholar 

  23. Peng WX, Koirala P, Mo YY. LncRNA-mediated regulation of cell signaling in cancer. Oncogene. 2017;36:5661–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Gil N, Ulitsky I. Regulation of gene expression by cis-acting long non-coding RNAs. Nat Rev Genet. 2020;21:102–17.

    Article  CAS  PubMed  Google Scholar 

  25. Ransohoff JD, Wei Y, Khavari PA. The functions and unique features of long intergenic non-coding RNA. Nat Rev Mol Cell Biol. 2018;19:143–57.

    Article  CAS  PubMed  Google Scholar 

  26. Liu SJ, Dang HX, Lim DA, Feng FY, Maher CA. Long noncoding RNAs in cancer metastasis. Nat Rev Cancer. 2021;21:446–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Tan YT, Lin JF, Li T, Li JJ, Xu RH, Ju HQ. LncRNA-mediated posttranslational modifications and reprogramming of energy metabolism in cancer. Cancer Commun. 2021;41:109–20.

    Article  Google Scholar 

  28. Chen Y, Li Z, Chen X, Zhang S. Long non-coding RNAs: From disease code to drug role. Acta Pharm Sin B. 2021;11:340–54.

    Article  CAS  PubMed  Google Scholar 

  29. Goyal B, Yadav SRM, Awasthee N, Gupta S, Kunnumakkara AB, Gupta SC. Diagnostic, prognostic, and therapeutic significance of long non-coding RNA MALAT1 in cancer. Biochim Biophys Acta Rev Cancer. 2021;1875:188502.

    Article  CAS  PubMed  Google Scholar 

  30. Derrien T, Johnson R, Bussotti G, Tanzer A, Djebali S, Tilgner H, et al. The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression. Genome Res. 2012;22:1775–89.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Statello L, Guo CJ, Chen LL, Huarte M. Gene regulation by long non-coding RNAs and its biological functions. Nat Rev Mol Cell Biol. 2021;22:96–118.

    Article  CAS  PubMed  Google Scholar 

  32. Herman AB, Tsitsipatis D, Gorospe M. Integrated lncRNA function upon genomic and epigenomic regulation. Mol Cell. 2022;82:2252–66.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Quinn JJ, Chang HY. Unique features of long non-coding RNA biogenesis and function. Nat Rev Genet. 2016;17:47–62.

    Article  CAS  PubMed  Google Scholar 

  34. Liu S, Cao Q, An G, Yan B, Lei L. Identification of the 3-lncRNA signature as a prognostic biomarker for colorectal cancer. Int J Mol Sci. 2020;21:9359.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Matsui M, Corey DR. Non-coding RNAs as drug targets. Nat Rev Drug Discov. 2017;16:167–79.

    Article  CAS  PubMed  Google Scholar 

  36. Hong J, Guo F, Lu SY, Shen C, Ma D, Zhang X, et al. F. nucleatum targets lncRNA ENO1-IT1 to promote glycolysis and oncogenesis in colorectal cancer. Gut. 2021;70:2123–37.

    Article  CAS  PubMed  Google Scholar 

  37. Feretzaki M, Pospisilova M, Valador Fernandes R, Lunardi T, Krejci L, Lingner J. RAD51-dependent recruitment of TERRA lncRNA to telomeres through R-loops. Nature. 2020;587:303–8.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Vohhodina J, Goehring LJ, Liu B, Kong Q, Botchkarev VV Jr, Huynh M, et al. BRCA1 binds TERRA RNA and suppresses R-Loop-based telomeric DNA damage. Nat Commun. 2021;12:3542.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Ma L, Xu A, Kang L, Cong R, Fan Z, Zhu X, et al. LSD1-Demethylated LINC01134 confers oxaliplatin resistance through SP1-induced p62 transcription in HCC. Hepatology. 2021;74:3213–34.

    Article  CAS  PubMed  Google Scholar 

  40. Zhou HZ, Li F, Cheng ST, Xu Y, Deng HJ, Gu DY, et al. DDX17-regulated alternative splicing that produced an oncogenic isoform of PXN-AS1 to promote HCC metastasis. Hepatology. 2022;75:847–65.

    Article  CAS  PubMed  Google Scholar 

  41. Morelli E, Fulciniti M, Samur MK, Ribeiro CF, Wert-Lamas L, Henninger JE, et al. A MIR17HG-derived long noncoding RNA provides an essential chromatin scaffold for protein interaction and myeloma growth. Blood. 2023;141:391–405.

    Article  CAS  PubMed  Google Scholar 

  42. Shi L, Magee P, Fassan M, Sahoo S, Leong HS, Lee D, et al. A KRAS-responsive long non-coding RNA controls microRNA processing. Nat Commun. 2021;12:2038.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Wang H, Huo X, Yang XR, He J, Cheng L, Wang N, et al. STAT3-mediated upregulation of lncRNA HOXD-AS1 as a ceRNA facilitates liver cancer metastasis by regulating SOX4. Mol Cancer. 2017;16:136.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Shi Q, Li Y, Li S, Jin L, Lai H, Wu Y, et al. LncRNA DILA1 inhibits Cyclin D1 degradation and contributes to tamoxifen resistance in breast cancer. Nat Commun. 2020;11:5513.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Ponting CP, Oliver PL, Reik W. Evolution and functions of long noncoding RNAs. Cell. 2009;136:629–41.

    Article  CAS  PubMed  Google Scholar 

  46. Kim TK, Hemberg M, Gray JM. Enhancer RNAs: a class of long noncoding RNAs synthesized at enhancers. Cold Spring Harb Perspect Biol. 2015;7:a018622.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Bridges MC, Daulagala AC, Kourtidis A. LNCcation: lncRNA localization and function. J Cell Biol. 2021;220:e202009045.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Rinn JL, Chang HY. Long noncoding RNAs: molecular modalities to organismal functions. Annu Rev Biochem. 2020;89:283–308.

    Article  CAS  PubMed  Google Scholar 

  49. Olivero CE, Martinez-Terroba E, Zimmer J, Liao C, Tesfaye E, Hooshdaran N, et al. p53 Activates the long noncoding RNA Pvt1b to inhibit Myc and suppress tumorigenesis. Mol Cell. 2020;77:761–74.e8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Zhu P, Wu J, Wang Y, Zhu X, Lu T, Liu B, et al. LncGata6 maintains stemness of intestinal stem cells and promotes intestinal tumorigenesis. Nat Cell Biol. 2018;20:1134–44.

    Article  CAS  PubMed  Google Scholar 

  51. Oeckinghaus A, Hayden MS, Ghosh S. Crosstalk in NF-kappaB signaling pathways. Nat Immunol. 2011;12:695–708.

    Article  CAS  PubMed  Google Scholar 

  52. Liu B, Sun L, Liu Q, Gong C, Yao Y, Lv X, et al. A cytoplasmic NF-kappaB interacting long noncoding RNA blocks IkappaB phosphorylation and suppresses breast cancer metastasis. Cancer Cell. 2015;27:370–81.

    Article  CAS  PubMed  Google Scholar 

  53. Shang Z, Yu J, Sun L, Tian J, Zhu S, Zhang B, et al. LncRNA PCAT1 activates AKT and NF-kappaB signaling in castration-resistant prostate cancer by regulating the PHLPP/FKBP51/IKKalpha complex. Nucleic Acids Res. 2019;47:4211–25.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Yang J, Nie J, Ma X, Wei Y, Peng Y, Wei X. Targeting PI3K in cancer: mechanisms and advances in clinical trials. Mol Cancer. 2019;18:26.

    Article  PubMed  PubMed Central  Google Scholar 

  55. Liu C, Zhang Y, She X, Fan L, Li P, Feng J, et al. A cytoplasmic long noncoding RNA LINC00470 as a new AKT activator to mediate glioblastoma cell autophagy. J Hematol Oncol. 2018;11:77.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Worby CA, Dixon JE. Pten. Annu Rev Biochem. 2014;83:641–69.

    Article  CAS  PubMed  Google Scholar 

  57. Alvarez-Garcia V, Tawil Y, Wise HM, Leslie NR. Mechanisms of PTEN loss in cancer: It’s all about diversity. Semin Cancer Biol. 2019;59:66–79.

    Article  CAS  PubMed  Google Scholar 

  58. Li W, Huang K, Wen F, Cui G, Guo H, He Z, et al. LINC00184 silencing inhibits glycolysis and restores mitochondrial oxidative phosphorylation in esophageal cancer through demethylation of PTEN. EBioMedicine. 2019;44:298–310.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Huang JZ, Chen M, Chen D, Gao XC, Zhu S, Huang H, et al. A peptide encoded by a putative lncRNA HOXB-AS3 suppresses colon cancer growth. Mol Cell. 2017;68:171–84.e6.

    Article  CAS  PubMed  Google Scholar 

  60. Wang Y, Wu S, Zhu X, Zhang L, Deng J, Li F, et al. LncRNA-encoded polypeptide ASRPS inhibits triple-negative breast cancer angiogenesis. J Exp Med. 2020;217:jem.20190950.

    Article  PubMed  Google Scholar 

  61. Wang J, Zhu S, Meng N, He Y, Lu R, Yan GR. ncRNA-encoded peptides or proteins and cancer. Mol Ther. 2019;27:1718–25.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Ye M, Zhang J, Wei M, Liu B, Dong K. Emerging role of long noncoding RNA-encoded micropeptides in cancer. Cancer Cell Int. 2020;20:506.

    Article  PubMed  PubMed Central  Google Scholar 

  63. Sun L, Wang W, Han C, Huang W, Sun Y, Fang K, et al. The oncomicropeptide APPLE promotes hematopoietic malignancy by enhancing translation initiation. Mol Cell. 2021;81:4493–508.e9.

    Article  CAS  PubMed  Google Scholar 

  64. Meng N, Chen M, Chen, Chen XH, Wang JZ, Zhu S, et al. Small protein hidden in lncRNA LOC90024 promotes “cancerous” RNA splicing and tumorigenesis. Adv Sci. 2020;7:1903233.

    Article  CAS  Google Scholar 

  65. Zhang C, Zhou B, Gu F, Liu H, Wu H, Yao F, et al. Micropeptide PACMP inhibition elicits synthetic lethal effects by decreasing CtIP and poly(ADP-ribosyl)ation. Mol Cell. 2022;82:1297–312.e8.

    Article  CAS  PubMed  Google Scholar 

  66. Barczak W, Carr SM, Liu G, Munro S, Nicastri A, Lee LN, et al. Long non-coding RNA-derived peptides are immunogenic and drive a potent anti-tumour response. Nat Commun. 2023;14:1078.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Fatica A, Bozzoni I. Long non-coding RNAs: new players in cell differentiation and development. Nat Rev Genet. 2014;15:7–21.

    Article  CAS  PubMed  Google Scholar 

  68. Yoon JH, Abdelmohsen K, Srikantan S, Yang X, Martindale JL, De S, et al. LincRNA-p21 suppresses target mRNA translation. Mol Cell. 2012;47:648–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Huarte M, Guttman M, Feldser D, Garber M, Koziol MJ, Kenzelmann-Broz D, et al. A large intergenic noncoding RNA induced by p53 mediates global gene repression in the p53 response. Cell. 2010;142:409–19.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Dimitrova N, Zamudio JR, Jong RM, Soukup D, Resnick R, Sarma K, et al. LincRNA-p21 activates p21 in cis to promote Polycomb target gene expression and to enforce the G1/S checkpoint. Mol Cell. 2014;54:777–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Winkler L, Jimenez M, Zimmer JT, Williams A, Simon MD, Dimitrova N. Functional elements of the cis-regulatory lincRNA-p21. Cell Rep. 2022;39:110687.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Furuhata R, Imasaka M, Sugimoto M, Yoshinobu K, Araki M, Araki K. LincRNA-p21 exon 1 expression correlates with Cdkn1a expression in vivo. Genes Cells. 2022;27:14–24.

    Article  CAS  PubMed  Google Scholar 

  73. Chen S, Liang H, Yang H, Zhou K, Xu L, Liu J, et al. LincRNa-p21: function and mechanism in cancer. Med Oncol. 2017;34:98.

    Article  PubMed  Google Scholar 

  74. Ao X, Jiang M, Zhou J, Liang H, Xia H, Chen G. lincRNAp21 inhibits the progression of nonsmall cell lung cancer via targeting miR175p. Oncol Rep. 2019;41:789–800.

    CAS  PubMed  Google Scholar 

  75. Wang B, Xu S, Wang T, Xu K, Yin L, Li X, et al. LincRNA-p21 promotes p21-mediated cell cycle arrest in benzene-induced hematotoxicity by sponging miRNA-17-5p. Environ Pollut. 2022;296:118706.

    Article  CAS  PubMed  Google Scholar 

  76. Jin S, Yang X, Li J, Yang W, Ma H, Zhang Z. p53-targeted lincRNA-p21 acts as a tumor suppressor by inhibiting JAK2/STAT3 signaling pathways in head and neck squamous cell carcinoma. Mol Cancer. 2019;18:38.

    Article  PubMed  PubMed Central  Google Scholar 

  77. Chou SD, Murshid A, Eguchi T, Gong J, Calderwood SK. HSF1 regulation of beta-catenin in mammary cancer cells through control of HuR/elavL1 expression. Oncogene. 2015;34:2178–88.

    Article  CAS  PubMed  Google Scholar 

  78. Yang F, Zhang H, Mei Y, Wu M. Reciprocal regulation of HIF-1alpha and lincRNA-p21 modulates the Warburg effect. Mol Cell. 2014;53:88–100.

    Article  CAS  PubMed  Google Scholar 

  79. Castellano JJ, Navarro A, Vinolas N, Marrades RM, Moises J, Cordeiro A, et al. LincRNA-p21 impacts prognosis in resected non-small cell lung cancer patients through angiogenesis regulation. J Thorac Oncol. 2016;11:2173–82.

    Article  PubMed  Google Scholar 

  80. Meng SS, Xu XP, Chang W, Lu ZH, Huang LL, Xu JY, et al. LincRNA-p21 promotes mesenchymal stem cell migration capacity and survival through hypoxic preconditioning. Stem Cell Res Ther. 2018;9:280.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Al-Rugeebah A, Alanazi M, Parine NR. MEG3: an oncogenic long non-coding RNA in different cancers. Pathol Oncol Res. 2019;25:859–74.

    Article  CAS  PubMed  Google Scholar 

  82. Zhou Y, Zhang X, Klibanski A. MEG3 noncoding RNA: a tumor suppressor. J Mol Endocrinol. 2012;48:R45–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  83. Buccarelli M, Lulli V, Giuliani A, Signore M, Martini M, D’Alessandris QG, et al. Deregulated expression of the imprinted DLK1-DIO3 region in glioblastoma stemlike cells: tumor suppressor role of lncRNA MEG3. Neuro Oncol. 2020;22:1771–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. Gong X, Huang M. Long non-coding RNA MEG3 promotes the proliferation of glioma cells through targeting Wnt/beta-catenin signal pathway. Cancer Gene Ther. 2017;24:381–5.

    Article  CAS  PubMed  Google Scholar 

  85. Zhu Y, Chen P, Gao Y, Ta N, Zhang Y, Cai J, et al. MEG3 activated by vitamin D inhibits colorectal cancer cells proliferation and migration via regulating clusterin. EBioMedicine 2018;30:148–57.

    Article  PubMed  PubMed Central  Google Scholar 

  86. Zhang W, Shi S, Jiang J, Li X, Lu H, Ren F. LncRNA MEG3 inhibits cell epithelial-mesenchymal transition by sponging miR-421 targeting E-cadherin in breast cancer. Biomed Pharmacother. 2017;91:312–9.

    Article  CAS  PubMed  Google Scholar 

  87. Yang Z, Wang Z, Duan Y. LncRNA MEG3 inhibits non-small cell lung cancer via interaction with DKC1 protein. Oncol Lett. 2020;20:2183–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  88. Hung T, Wang Y, Lin MF, Koegel AK, Kotake Y, Grant GD, et al. Extensive and coordinated transcription of noncoding RNAs within cell-cycle promoters. Nat Genet. 2011;43:621–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  89. Kotake Y, Goto T, Naemura M, Inoue Y, Okamoto H, Tahara K. Long noncoding RNA PANDA positively regulates proliferation of osteosarcoma cells. Anticancer Res. 2017;37:81–5.

    Article  PubMed  Google Scholar 

  90. Shi W, Wang Q, Bian Y, Fan Y, Zhou Y, Feng T, et al. Long noncoding RNA PANDA promotes esophageal squamous carcinoma cell progress by dissociating from NF-YA but interact with SAFA. Pathol Res Pr. 2019;215:152604.

    Article  CAS  Google Scholar 

  91. Puvvula PK, Desetty RD, Pineau P, Marchio A, Moon A, Dejean A, et al. Long noncoding RNA PANDA and scaffold-attachment-factor SAFA control senescence entry and exit. Nat Commun. 2014;5:5323.

    Article  PubMed  Google Scholar 

  92. Sun Q, Hao Q, Prasanth KV. Nuclear long noncoding RNAs: key regulators of gene expression. Trends Genet. 2018;34:142–57.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  93. Chaleshi V, Irani S, Alebouyeh M, Mirfakhraie R, Aghdaei HA. Association of lncRNA-p53 regulatory network (lincRNA-p21, lincRNA-ROR and MALAT1) and p53 with the clinicopathological features of colorectal primary lesions and tumors. Oncol Lett. 2020;19:3937–49.

    CAS  PubMed  PubMed Central  Google Scholar 

  94. Tano K, Onoguchi-Mizutani R, Yeasmin F, Uchiumi F, Suzuki Y, Yada T, et al. Identification of minimal p53 promoter region regulated by MALAT1 in human lung adenocarcinoma cells. Front Genet. 2017;8:208.

    Article  PubMed  Google Scholar 

  95. Chen R, Liu Y, Zhuang H, Yang B, Hei K, Xiao M, et al. Quantitative proteomics reveals that long non-coding RNA MALAT1 interacts with DBC1 to regulate p53 acetylation. Nucleic Acids Res. 2017;45:9947–59.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  96. Pruszko M, Milano E, Forcato M, Donzelli S, Ganci F, Di Agostino S, et al. The mutant p53-ID4 complex controls VEGFA isoforms by recruiting lncRNA MALAT1. EMBO Rep. 2017;18:1331–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  97. Kim SS, Harford JB, Moghe M, Rait A, Pirollo KF, Chang EH. Targeted nanocomplex carrying siRNA against MALAT1 sensitizes glioblastoma to temozolomide. Nucleic Acids Res. 2018;46:1424–40.

    Article  CAS  PubMed  Google Scholar 

  98. Kim J, Piao HL, Kim BJ, Yao F, Han Z, Wang Y, et al. Long noncoding RNA MALAT1 suppresses breast cancer metastasis. Nat Genet. 2018;50:1705–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  99. Schmidt LH, Spieker T, Koschmieder S, Schaffers S, Humberg J, Jungen D, et al. The long noncoding MALAT-1 RNA indicates a poor prognosis in non-small cell lung cancer and induces migration and tumor growth. J Thorac Oncol. 2011;6:1984–92.

    Article  PubMed  Google Scholar 

  100. Jen J, Tang YA, Lu YH, Lin CC, Lai WW, Wang YC. Oct4 transcriptionally regulates the expression of long non-coding RNAs NEAT1 and MALAT1 to promote lung cancer progression. Mol Cancer. 2017;16:104.

    Article  PubMed  PubMed Central  Google Scholar 

  101. Malakar P, Stein I, Saragovi A, Winkler R, Stern-Ginossar N, Berger M, et al. Long noncoding RNA MALAT1 regulates cancer glucose metabolism by enhancing mTOR-mediated translation of TCF7L2. Cancer Res. 2019;79:2480–93.

    Article  CAS  PubMed  Google Scholar 

  102. Adriaens C, Standaert L, Barra J, Latil M, Verfaillie A, Kalev P, et al. p53 induces formation of NEAT1 lncRNA-containing paraspeckles that modulate replication stress response and chemosensitivity. Nat Med. 2016;22:861–8.

    Article  CAS  PubMed  Google Scholar 

  103. Yuan J, Zhu Q, Zhang X, Wen Z, Zhang G, Li N, et al. Ezh2 competes with p53 to license lncRNA Neat1 transcription for inflammasome activation. Cell Death Differ. 2022;29:2009–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  104. Ma F, Lei YY, Ding MG, Luo LH, Xie YC, Liu XL. LncRNA NEAT1 interacted with DNMT1 to regulate malignant phenotype of cancer cell and cytotoxic T cell infiltration via epigenetic inhibition of p53, cGAS, and STING in lung cancer. Front Genet. 2020;11:250.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  105. Mello SS, Sinow C, Raj N, Mazur PK, Bieging-Rolett K, Broz DK, et al. Neat1 is a p53-inducible lincRNA essential for transformation suppression. Genes Dev. 2017;31:1095–108.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  106. Idogawa M, Nakase H, Sasaki Y, Tokino T. Prognostic effect of long noncoding RNA NEAT1 expression depends on p53 mutation status in cancer. J Oncol. 2019;2019:4368068.

    PubMed  PubMed Central  Google Scholar 

  107. Blume CJ, Hotz-Wagenblatt A, Hullein J, Sellner L, Jethwa A, Stolz T, et al. p53-dependent non-coding RNA networks in chronic lymphocytic leukemia. Leukemia. 2015;29:2015–23.

    Article  CAS  PubMed  Google Scholar 

  108. Idogawa M, Ohashi T, Sasaki Y, Nakase H, Tokino T. Long non-coding RNA NEAT1 is a transcriptional target of p53 and modulates p53-induced transactivation and tumor-suppressor function. Int J Cancer. 2017;140:2785–91.

    Article  CAS  PubMed  Google Scholar 

  109. Shin VY, Chen J, Cheuk IW, Siu MT, Ho CW, Wang X, et al. Long non-coding RNA NEAT1 confers oncogenic role in triple-negative breast cancer through modulating chemoresistance and cancer stemness. Cell Death Dis. 2019;10:270.

    Article  PubMed  PubMed Central  Google Scholar 

  110. Ghafouri-Fard S, Esmaeili M, Taheri M. H19 lncRNA: roles in tumorigenesis. Biomed Pharmacother. 2020;123:109774.

    Article  CAS  PubMed  Google Scholar 

  111. Yang J, Qi M, Fei X, Wang X, Wang K. LncRNA H19: a novel oncogene in multiple cancers. Int J Biol Sci. 2021;17:3188–208.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  112. Park KS, Mitra A, Rahat B, Kim K, Pfeifer K. Loss of imprinting mutations define both distinct and overlapping roles for misexpression of IGF2 and of H19 lncRNA. Nucleic Acids Res. 2017;45:12766–79.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  113. Gan L, Liao S, Tong Y, Li W, Peng W, Deng S. Long noncoding RNA H19 mediates neural stem/progenitor cells proliferation, differentiation and apoptosis through the p53 signaling pathway after ischemic stroke. Biochem Biophys Res Commun. 2022;597:8–15.

    Article  CAS  PubMed  Google Scholar 

  114. Zheng ZH, Wu DM, Fan SH, Zhang ZF, Chen GQ, Lu J. Upregulation of miR-675-5p induced by lncRNA H19 was associated with tumor progression and development by targeting tumor suppressor p53 in non-small cell lung cancer. J Cell Biochem. 2019;120:18724–35.

    Article  CAS  PubMed  Google Scholar 

  115. Li J, Zhang Y, Sun L, Liu S, Zhao M, Luo B. LMP1 induces p53 protein expression via the H19/miR-675-5p axis. Microbiol Spectr. 2022;10:e0000622.

    Article  PubMed  Google Scholar 

  116. Cen B, Lang JD, Du Y, Wei J, Xiong Y, Bradley N, et al. Prostaglandin E2 induces miR675-5p to promote colorectal tumor metastasis via modulation of p53 expression. Gastroenterology. 2020;158:971–84.e10.

    Article  CAS  PubMed  Google Scholar 

  117. Huang Z, Chu L, Liang J, Tan X, Wang Y, Wen J, et al. H19 promotes HCC bone metastasis through reducing osteoprotegerin expression in a protein phosphatase 1 catalytic subunit alpha/p38 mitogen-activated protein kinase-dependent manner and sponging microRNA 200b-3p. Hepatology. 2021;74:214–32.

    Article  CAS  PubMed  Google Scholar 

  118. Zhang Y, Huang W, Yuan Y, Li J, Wu J, Yu J, et al. Long non-coding RNA H19 promotes colorectal cancer metastasis via binding to hnRNPA2B1. J Exp Clin Cancer Res. 2020;39:141.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  119. Zhang A, Zhou N, Huang J, Liu Q, Fukuda K, Ma D, et al. The human long non-coding RNA-RoR is a p53 repressor in response to DNA damage. Cell Res. 2013;23:340–50.

    Article  CAS  PubMed  Google Scholar 

  120. Meza-Sosa KF, Miao R, Navarro F, Zhang Z, Zhang Y, Hu JJ, et al. SPARCLE, a p53-induced lncRNA, controls apoptosis after genotoxic stress by promoting PARP-1 cleavage. Mol Cell. 2022;82:785–802.e10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  121. Schmitt AM, Garcia JT, Hung T, Flynn RA, Shen Y, Qu K, et al. An inducible long noncoding RNA amplifies DNA damage signaling. Nat Genet. 2016;48:1370–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  122. Hu WL, Jin L, Xu A, Wang YF, Thorne RF, Zhang XD, et al. GUARDIN is a p53-responsive long non-coding RNA that is essential for genomic stability. Nat Cell Biol. 2018;20:492–502.

    Article  PubMed  Google Scholar 

  123. Zafar A, Wang W, Liu G, Xian W, McKeon F, Zhou J, et al. Targeting the p53-MDM2 pathway for neuroblastoma therapy: rays of hope. Cancer Lett. 2021;496:16–29.

    Article  CAS  PubMed  Google Scholar 

  124. Wu D, Prives C. Relevance of the p53-MDM2 axis to aging. Cell Death Differ. 2018;25:169–79.

    Article  CAS  PubMed  Google Scholar 

  125. Zhou CC, Yang F, Yuan SX, Ma JZ, Liu F, Yuan JH, et al. Systemic genome screening identifies the outcome associated focal loss of long noncoding RNA PRAL in hepatocellular carcinoma. Hepatology. 2016;63:850–63.

    Article  CAS  PubMed  Google Scholar 

  126. Deng X, Li S, Kong F, Ruan H, Xu X, Zhang X, et al. Long noncoding RNA PiHL regulates p53 protein stability through GRWD1/RPL11/MDM2 axis in colorectal cancer. Theranostics. 2020;10:265–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  127. Wu G, Cai J, Han Y, Chen J, Huang ZP, Chen C, et al. LincRNA-p21 regulates neointima formation, vascular smooth muscle cell proliferation, apoptosis, and atherosclerosis by enhancing p53 activity. Circulation. 2014;130:1452–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  128. Ding X, Jia X, Wang C, Xu J, Gao SJ, Lu C. A DHX9-lncRNA-MDM2 interaction regulates cell invasion and angiogenesis of cervical cancer. Cell Death Differ. 2019;26:1750–65.

    Article  CAS  PubMed  Google Scholar 

  129. Feng YC, Liu XY, Teng L, Ji Q, Wu Y, Li JM, et al. c-Myc inactivation of p53 through the pan-cancer lncRNA MILIP drives cancer pathogenesis. Nat Commun. 2020;11:4980.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  130. Cho SW, Xu J, Sun R, Mumbach MR, Carter AC, Chen YG, et al. Promoter of lncRNA gene PVT1 is a tumor-suppressor DNA boundary element. Cell. 2018;173:1398–412.e22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  131. Wu QN, Luo XJ, Liu J, Lu YX, Wang Y, Qi J, et al. MYC-activated LncRNA MNX1-AS1 promotes the progression of colorectal cancer by stabilizing YB1. Cancer Res. 2021;81:2636–50.

    Article  CAS  PubMed  Google Scholar 

  132. Wang R, Ma Z, Feng L, Yang Y, Tan C, Shi Q, et al. LncRNA MIR31HG targets HIF1A and P21 to facilitate head and neck cancer cell proliferation and tumorigenesis by promoting cell-cycle progression. Mol Cancer. 2018;17:162.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  133. Liu HT, Liu S, Liu L, Ma RR, Gao P. EGR1-mediated transcription of lncRNA-HNF1A-AS1 promotes cell-cycle progression in gastric cancer. Cancer Res. 2018;78:5877–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  134. Fang P, Chen H, Ma Z, Han C, Yin W, Wang S, et al. LncRNA LINC00525 suppresses p21 expression via mRNA decay and triplex-mediated changes in chromatin structure in lung adenocarcinoma. Cancer Commun. 2021;41:596–614.

    Article  Google Scholar 

  135. Wang Z, Yang B, Zhang M, Guo W, Wu Z, Wang Y, et al. lncRNA epigenetic landscape analysis identifies EPIC1 as an oncogenic lncRNA that interacts with MYC and promotes cell-cycle progression in cancer. Cancer Cell. 2018;33:706–20.e9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  136. Bhan A, Soleimani M, Mandal SS. Long noncoding RNA and cancer: a new paradigm. Cancer Res. 2017;77:3965–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  137. Shima H, Kida K, Adachi S, Yamada A, Sugae S, Narui K, et al. Lnc RNA H19 is associated with poor prognosis in breast cancer patients and promotes cancer stemness. Breast Cancer Res Treat. 2018;170:507–16.

    Article  CAS  PubMed  Google Scholar 

  138. Wang J, Yang K, Yuan W, Gao Z. Determination of serum exosomal H19 as a noninvasive biomarker for bladder cancer diagnosis and prognosis. Med Sci Monit. 2018;24:9307–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  139. Li Z, Meng X, Wu P, Zha C, Han B, Li L, et al. Glioblastoma cell-derived lncRNA-containing exosomes induce microglia to produce complement C5, promoting chemotherapy resistance. Cancer Immunol Res. 2021;9:1383–99.

    Article  CAS  PubMed  Google Scholar 

  140. Arun G, Diermeier S, Akerman M, Chang KC, Wilkinson JE, Hearn S, et al. Differentiation of mammary tumors and reduction in metastasis upon Malat1 lncRNA loss. Genes Dev. 2016;30:34–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  141. Li W, Zhang Z, Liu X, Cheng X, Zhang Y, Han X, et al. The FOXN3-NEAT1-SIN3A repressor complex promotes progression of hormonally responsive breast cancer. J Clin Invest. 2017;127:3421–40.

    Article  PubMed  PubMed Central  Google Scholar 

  142. Zhang L, Song X, Wang X, Xie Y, Wang Z, Xu Y, et al. Circulating DNA of HOTAIR in serum is a novel biomarker for breast cancer. Breast Cancer Res Treat. 2015;152:199–208.

    Article  CAS  PubMed  Google Scholar 

  143. Sorensen KP, Thomassen M, Tan Q, Bak M, Cold S, Burton M, et al. Long non-coding RNA HOTAIR is an independent prognostic marker of metastasis in estrogen receptor-positive primary breast cancer. Breast Cancer Res Treat. 2013;142:529–36.

    Article  PubMed  Google Scholar 

  144. Di Fusco D, Dinallo V, Marafini I, Figliuzzi MM, Romano B, Monteleone G. Antisense oligonucleotide: basic concepts and therapeutic application in inflammatory bowel disease. Front Pharm. 2019;10:305.

    Article  Google Scholar 

  145. Ramasamy T, Ruttala HB, Munusamy S, Chakraborty N, Kim JO. Nano drug delivery systems for antisense oligonucleotides (ASO) therapeutics. J Control Release. 2022;352:861–78.

    Article  CAS  PubMed  Google Scholar 

  146. Arora V, Iversen PL. Antisense oligonucleotides targeted to the p53 gene modulate liver regeneration in vivo. Drug Metab Dispos. 2000;28:131–8.

    CAS  PubMed  Google Scholar 

  147. Barton CM, Lemoine NR. Antisense oligonucleotides directed against p53 have antiproliferative effects unrelated to effects on p53 expression. Br J Cancer. 1995;71:429–37.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  148. Micheletti R, Plaisance I, Abraham BJ, Sarre A, Ting CC, Alexanian M, et al. The long noncoding RNA Wisper controls cardiac fibrosis and remodeling. Sci Transl Med. 2017;9:eaai9118.

    Article  PubMed  PubMed Central  Google Scholar 

  149. Yang K, Zhang W, Zhong L, Xiao Y, Sahoo S, Fassan M, et al. Long non-coding RNA HIF1A-As2 and MYC form a double-positive feedback loop to promote cell proliferation and metastasis in KRAS-driven non-small cell lung cancer. Cell Death Differ. 2023;30:1533–49.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  150. Li Y, Ren Y, Wang Y, Tan Y, Wang Q, Cai J, et al. A compound AC1Q3QWB selectively disrupts HOTAIR-mediated recruitment of PRC2 and enhances cancer therapy of DZNep. Theranostics. 2019;9:4608–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  151. Chen S, Sbuh N, Veedu RN. Antisense oligonucleotides as potential therapeutics for type 2 diabetes. Nucleic Acid Ther. 2021;31:39–57.

    Article  PubMed  Google Scholar 

  152. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7–30.

    Article  PubMed  Google Scholar 

  153. Duffy MJ, Synnott NC, Crown J. Mutant p53 as a target for cancer treatment. Eur J Cancer. 2017;83:258–65.

    Article  CAS  PubMed  Google Scholar 

  154. Halazonetis TD, Gorgoulis VG, Bartek J. An oncogene-induced DNA damage model for cancer development. Science. 2008;319:1352–5.

    Article  CAS  PubMed  Google Scholar 

  155. Levine AJ. p53: 800 million years of evolution and 40 years of discovery. Nat Rev Cancer. 2020;20:471–80.

    Article  CAS  PubMed  Google Scholar 

  156. Spencer HL, Sanders R, Boulberdaa M, Meloni M, Cochrane A, Spiroski AM, et al. The LINC00961 transcript and its encoded micropeptide, small regulatory polypeptide of amino acid response, regulate endothelial cell function. Cardiovasc Res. 2020;116:1981–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  157. Polycarpou-Schwarz M, Gross M, Mestdagh P, Schott J, Grund SE, Hildenbrand C, et al. The cancer-associated microprotein CASIMO1 controls cell proliferation and interacts with squalene epoxidase modulating lipid droplet formation. Oncogene. 2018;37:4750–68.

    Article  CAS  PubMed  Google Scholar 

  158. Wu S, Guo B, Zhang L, Zhu X, Zhao P, Deng J, et al. A micropeptide XBP1SBM encoded by lncRNA promotes angiogenesis and metastasis of TNBC via XBP1s pathway. Oncogene. 2022;41:2163–72.

    Article  CAS  PubMed  Google Scholar 

  159. Guo B, Wu S, Zhu X, Zhang L, Deng J, Li F, et al. Micropeptide CIP2A-BP encoded by LINC00665 inhibits triple-negative breast cancer progression. EMBO J. 2020;39:e102190.

    Article  CAS  PubMed  Google Scholar 

  160. D’Lima NG, Ma J, Winkler L, Chu Q, Loh KH, Corpuz EO, et al. A human microprotein that interacts with the mRNA decapping complex. Nat Chem Biol. 2017;13:174–80.

    Article  PubMed  Google Scholar 

  161. Wang X, Zhang H, Yin S, Yang Y, Yang H, Yang J, et al. lncRNA-encoded pep-AP attenuates the pentose phosphate pathway and sensitizes colorectal cancer cells to Oxaliplatin. EMBO Rep. 2022;23:e53140.

    Article  CAS  PubMed  Google Scholar 

  162. Li XL, Pongor L, Tang W, Das S, Muys BR, Jones MF, et al. A small protein encoded by a putative lncRNA regulates apoptosis and tumorigenicity in human colorectal cancer cells. Elife. 2020;9:e53734.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  163. Zhu S, Wang JZ, Chen D, He YT, Meng N, Chen M, et al. An oncopeptide regulates m(6)A recognition by the m(6)A reader IGF2BP1 and tumorigenesis. Nat Commun. 2020;11:1685.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  164. Ge Q, Jia D, Cen D, Qi Y, Shi C, Li J, et al. Micropeptide ASAP encoded by LINC00467 promotes colorectal cancer progression by directly modulating ATP synthase activity. J Clin Invest. 2021;131:e152911.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  165. Wu S, Zhang L, Deng J, Guo B, Li F, Wang Y, et al. A novel micropeptide encoded by Y-linked LINC00278 links cigarette smoking and AR signaling in male esophageal squamous cell carcinoma. Cancer Res. 2020;80:2790–803.

    Article  CAS  PubMed  Google Scholar 

  166. Polenkowski M, Burbano de Lara S, Allister AB, Nguyen TNQ, Tamura T, Tran DDH. Identification of novel micropeptides derived from hepatocellular carcinoma-specific long noncoding RNA. Int J Mol Sci. 2021;23:58.

    Article  PubMed  PubMed Central  Google Scholar 

  167. Pang Y, Liu Z, Han H, Wang B, Li W, Mao C, et al. Peptide SMIM30 promotes HCC development by inducing SRC/YES1 membrane anchoring and MAPK pathway activation. J Hepatol. 2020;73:1155–69.

    Article  CAS  PubMed  Google Scholar 

  168. Xu W, Deng B, Lin P, Liu C, Li B, Huang Q, et al. Ribosome profiling analysis identified a KRAS-interacting microprotein that represses oncogenic signaling in hepatocellular carcinoma cells. Sci China Life Sci. 2020;63:529–42.

    Article  CAS  PubMed  Google Scholar 

  169. Xiang X, Fu Y, Zhao K, Miao R, Zhang X, Ma X, et al. Cellular senescence in hepatocellular carcinoma induced by a long non-coding RNA-encoded peptide PINT87aa by blocking FOXM1-mediated PHB2. Theranostics. 2021;11:4929–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  170. Bhatta A, Atianand M, Jiang Z, Crabtree J, Blin J, Fitzgerald KA. A mitochondrial micropeptide is required for activation of the Nlrp3 inflammasome. J Immunol. 2020;204:428–37.

    Article  CAS  PubMed  Google Scholar 

  171. Lu S, Zhang J, Lian X, Sun L, Meng K, Chen Y, et al. A hidden human proteome encoded by ‘non-coding’ genes. Nucleic Acids Res. 2019;47:8111–25.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  172. Godet Y, Moreau-Aubry A, Guilloux Y, Vignard V, Khammari A, Dreno B, et al. MELOE-1 is a new antigen overexpressed in melanomas and involved in adoptive T cell transfer efficiency. J Exp Med. 2008;205:2673–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  173. Charpentier M, Dupre E, Fortun A, Briand F, Maillasson M, Com E, et al. hnRNP-A1 binds to the IRES of MELOE-1 antigen to promote MELOE-1 translation in stressed melanoma cells. Mol Oncol. 2022;16:594–606.

    Article  CAS  PubMed  Google Scholar 

  174. Matsumoto A, Pasut A, Matsumoto M, Yamashita R, Fung J, Monteleone E, et al. mTORC1 and muscle regeneration are regulated by the LINC00961-encoded SPAR polypeptide. Nature. 2017;541:228–32.

    Article  CAS  PubMed  Google Scholar 

  175. Anderson DM, Anderson KM, Chang CL, Makarewich CA, Nelson BR, McAnally JR, et al. A micropeptide encoded by a putative long noncoding RNA regulates muscle performance. Cell. 2015;160:595–606.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  176. Nelson BR, Makarewich CA, Anderson DM, Winders BR, Troupes CD, Wu F, et al. A peptide encoded by a transcript annotated as long noncoding RNA enhances SERCA activity in muscle. Science. 2016;351:271–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  177. Makarewich CA, Bezprozvannaya S, Gibson AM, Bassel-Duby R, Olson EN. Gene therapy with the DWORF micropeptide attenuates cardiomyopathy in mice. Circ Res. 2020;127:1340–2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  178. Zhang Q, Vashisht AA, O’Rourke J, Corbel SY, Moran R, Romero A, et al. The microprotein Minion controls cell fusion and muscle formation. Nat Commun. 2017;8:15664.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  179. Tesfaye E, Martinez-Terroba E, Bendor J, Winkler L, Olivero C, Chen K, et al. The p53 transcriptional response across tumor types reveals core and senescence-specific signatures modulated by long noncoding RNAs. Proc Natl Acad Sci USA. 2021;118:e2025539118.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  180. Dang W, Cao P, Yan Q, Yang L, Wang Y, Yang J, et al. IGFBP7-AS1 is a p53-responsive long noncoding RNA downregulated by Epstein-Barr virus that contributes to viral tumorigenesis. Cancer Lett. 2021;523:135–47.

    Article  CAS  PubMed  Google Scholar 

  181. Mitra S, Muralidharan SV, Di Marco M, Juvvuna PK, Kosalai ST, Reischl S, et al. Subcellular distribution of p53 by the p53-responsive lncRNA NBAT1 determines chemotherapeutic response in neuroblastoma. Cancer Res. 2021;81:1457–71.

    Article  CAS  PubMed  Google Scholar 

  182. Wang D, Wan X, Zhang Y, Kong Z, Lu Y, Sun X, et al. A novel androgen-reduced prostate-specific lncRNA, PSLNR, inhibits prostate-cancer progression in part by regulating the p53-dependent pathway. Prostate. 2019;79:1362–77.

    Article  CAS  PubMed  Google Scholar 

  183. Qin G, Tu X, Li H, Cao P, Chen X, Song J, et al. Long noncoding RNA p53-stabilizing and activating RNA promotes p53 signaling by inhibiting heterogeneous nuclear ribonucleoprotein K deSUMOylation and suppresses hepatocellular carcinoma. Hepatology. 2020;71:112–29.

    Article  CAS  PubMed  Google Scholar 

  184. Mao C, Wang X, Liu Y, Wang M, Yan B, Jiang Y, et al. A G3BP1-interacting lncRNA promotes ferroptosis and apoptosis in cancer via nuclear sequestration of p53. Cancer Res. 2018;78:3484–96.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  185. Shen Y, Liu S, Fan J, Jin Y, Tian B, Zheng X, et al. Nuclear retention of the lncRNA SNHG1 by doxorubicin attenuates hnRNPC-p53 protein interactions. EMBO Rep. 2017;18:536–48.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  186. Uroda T, Anastasakou E, Rossi A, Teulon JM, Pellequer JL, Annibale P, et al. Conserved pseudoknots in lncRNA MEG3 are essential for stimulation of the p53 pathway. Mol Cell. 2019;75:982–95.e9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  187. Lyu Y, Lou J, Yang Y, Feng J, Hao Y, Huang S, et al. Dysfunction of the WT1-MEG3 signaling promotes AML leukemogenesis via p53-dependent and -independent pathways. Leukemia. 2017;31:2543–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  188. Melo CA, Leveille N, Rooijers K, Wijchers PJ, Geeven G, Tal A, et al. A p53-bound enhancer region controls a long intergenic noncoding RNA required for p53 stress response. Oncogene. 2016;35:4399–406.

    Article  CAS  PubMed  Google Scholar 

  189. Zehendner CM, Valasarajan C, Werner A, Boeckel JN, Bischoff FC, John D, et al. Long noncoding RNA TYKRIL plays a role in pulmonary hypertension via the p53-mediated regulation of PDGFRbeta. Am J Respir Crit Care Med. 2020;202:1445–57.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  190. Marchese FP, Grossi E, Marin-Bejar O, Bharti SK, Raimondi I, Gonzalez J, et al. A long noncoding RNA regulates sister chromatid cohesion. Mol Cell. 2016;63:397–407.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  191. Xu CL, Sang B, Liu GZ, Li JM, Zhang XD, Liu LX, et al. SENEBLOC, a long non-coding RNA suppresses senescence via p53-dependent and independent mechanisms. Nucleic Acids Res. 2020;48:3089–102.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  192. Marney CB, Anderson ES, Adnan M, Peng KL, Hu Y, Weinhold N, et al. p53-intact cancers escape tumor suppression through loss of long noncoding RNA Dino. Cell Rep. 2021;35:109329.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  193. Wang H, Fang L, Jiang J, Kuang Y, Wang B, Shang X, et al. The cisplatin-induced lncRNA PANDAR dictates the chemoresistance of ovarian cancer via regulating SFRS2-mediated p53 phosphorylation. Cell Death Dis. 2018;9:1103.

    Article  PubMed  PubMed Central  Google Scholar 

  194. Chen Y, Hao Q, Wang S, Cao M, Huang Y, Weng X, et al. Inactivation of the tumor suppressor p53 by long noncoding RNA RMRP. Proc Natl Acad Sci USA. 2021;118:e2026813118.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  195. Amirinejad R, Rezaei M, Shirvani-Farsani Z. An update on long intergenic noncoding RNA p21: a regulatory molecule with various significant functions in cancer. Cell Biosci. 2020;10:82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  196. Hall JR, Messenger ZJ, Tam HW, Phillips SL, Recio L, Smart RC. Long noncoding RNA lincRNA-p21 is the major mediator of UVB-induced and p53-dependent apoptosis in keratinocytes. Cell Death Dis. 2015;6:e1700.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  197. Ye Y, He X, Lu F, Mao H, Zhu Z, Yao L, et al. A lincRNA-p21/miR-181 family feedback loop regulates microglial activation during systemic LPS- and MPTP- induced neuroinflammation. Cell Death Dis. 2018;9:803.

    Article  PubMed  PubMed Central  Google Scholar 

  198. Bao X, Wu H, Zhu X, Guo X, Hutchins AP, Luo Z, et al. The p53-induced lincRNA-p21 derails somatic cell reprogramming by sustaining H3K9me3 and CpG methylation at pluripotency gene promoters. Cell Res. 2015;25:80–92.

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

This study was supported by the National Natural Science Foundation of China (Grant No. 82273001), Central Double First-Class Universities Construction Fund of Lanzhou University (Grant No. 561121202), Gansu Province College Youth Doctoral Fund Project (Grant No. 2022QB-006), Medical Innovation and Development Project of Lanzhou University (Grant No. lzuyxcx-2022-163) and Department of Education of Gansu Province: Excellent graduate student ‘Innovation Star’ project (2023CXZX-150).

Author information

Author notes

  1. These authors contributed equally: Kaixin Yang, Yinan Xiao.

Authors and Affiliations

  1. RNA Oncology Group, School of Public Health, Lanzhou University, Lanzhou, 730000, People’s Republic of China

    Kaixin Yang, Yinan Xiao, Linghui Zhong, Wenyang Zhang, Yaru Ren & Lei Shi

  2. College of Animal Science and Technology, Hebei North University, Zhangjiakou, 075131, People’s Republic of China

    Peng Wang

Authors
  1. Kaixin Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yinan Xiao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Linghui Zhong
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wenyang Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Peng Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yaru Ren
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Lei Shi
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

KXY, YNX, and LS conceptualized the review, performed the literature search, and wrote the manuscript. LHZ, WYZ, PW, and YRR helped to edit the manuscript. All authors read and approved the final manuscript. LS revised each step of the work and are responsible for the final revision.

Corresponding author

Correspondence to Lei Shi.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yang, K., Xiao, Y., Zhong, L. et al. p53-regulated lncRNAs in cancers: from proliferation and metastasis to therapy. Cancer Gene Ther 30, 1456–1470 (2023). https://doi.org/10.1038/s41417-023-00662-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41417-023-00662-7

Search

Advanced search

Quick links